Cargando…
HLA genetic polymorphisms and prognosis of patients with COVID-19
OBJECTIVE: Different genetic polymorphisms of human leukocyte antigen (HLA) have been associated with the risk and prognosis of autoimmune and infectious diseases. The objectives of this study were to determine whether there is an association between HLA genetic polymorphisms and the susceptibility...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier España, S.L.U. y SEMICYUC.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7474921/ http://dx.doi.org/10.1016/j.medin.2020.08.004 |
_version_ | 1783579417611599872 |
---|---|
author | Lorente, L. Martín, M.M. Franco, A. Barrios, Y. Cáceres, J.J. Solé-Violán, J. Perez, A. Marcos y Ramos, J.A. Ramos-Gómez, L. Ojeda, N. Jiménez, A. |
author_facet | Lorente, L. Martín, M.M. Franco, A. Barrios, Y. Cáceres, J.J. Solé-Violán, J. Perez, A. Marcos y Ramos, J.A. Ramos-Gómez, L. Ojeda, N. Jiménez, A. |
author_sort | Lorente, L. |
collection | PubMed |
description | OBJECTIVE: Different genetic polymorphisms of human leukocyte antigen (HLA) have been associated with the risk and prognosis of autoimmune and infectious diseases. The objectives of this study were to determine whether there is an association between HLA genetic polymorphisms and the susceptibility to and mortality of coronavirus disease 2019 (COVID-19) patients. DESIGN: Observational and prospective study. SETTING: Eight Intensive Care Units (ICU) from 6 hospitals of Canary Islands (Spain). PATIENTS: COVID-19 patients admitted in ICU and healthy subjects. INTERVENTIONS: Determination of HLA genetic polymorphisms. MAIN VARIABLE OF INTEREST: Mortality at 30 days. RESULTS: A total of 3886 healthy controls and 72 COVID-19 patients (10 non-survivors and 62 survivor patients at 30 days) were included. We found a trend to a higher rate of the alleles HLA-A*32 (p = 0.004) in healthy controls than in COVID-19 patients, and of the alleles HLA-B*39 (p = 0.02) and HLA-C*16 (p = 0.02) in COVID-19 patients than in healthy controls; however, all these p-values were not significant after correction for multiple comparisons. Logistic regression analysis showed that the presence of certain alleles was associated with higher mortality, such as the allele HLA-A*11 after controlling for SOFA (OR = 7.693; 95% CI = 1.063–55.650; p = 0.04) or APACHE-II (OR = 11.858; 95% CI = 1.524–92.273; p = 0.02), the allele HLA-C*01 after controlling for SOFA (OR = 11.182; 95% CI = 1.053–118.700; p = 0.04) or APACHE-II (OR = 17.604; 95% CI = 1.629–190.211; p = 0.02), and the allele HLA-DQB1*04 after controlling for SOFA (OR = 9.963; 95% CI = 1.235–80.358; p = 0.03). CONCLUSIONS: The new finding from our preliminary study of small sample size was that HLA genetic polymorphisms could be associated with COVID-19 mortality; however, studies with a larger sample size before definitive conclusions can be drawn. |
format | Online Article Text |
id | pubmed-7474921 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Elsevier España, S.L.U. y SEMICYUC. |
record_format | MEDLINE/PubMed |
spelling | pubmed-74749212020-09-08 HLA genetic polymorphisms and prognosis of patients with COVID-19 Lorente, L. Martín, M.M. Franco, A. Barrios, Y. Cáceres, J.J. Solé-Violán, J. Perez, A. Marcos y Ramos, J.A. Ramos-Gómez, L. Ojeda, N. Jiménez, A. Med Intensiva Original OBJECTIVE: Different genetic polymorphisms of human leukocyte antigen (HLA) have been associated with the risk and prognosis of autoimmune and infectious diseases. The objectives of this study were to determine whether there is an association between HLA genetic polymorphisms and the susceptibility to and mortality of coronavirus disease 2019 (COVID-19) patients. DESIGN: Observational and prospective study. SETTING: Eight Intensive Care Units (ICU) from 6 hospitals of Canary Islands (Spain). PATIENTS: COVID-19 patients admitted in ICU and healthy subjects. INTERVENTIONS: Determination of HLA genetic polymorphisms. MAIN VARIABLE OF INTEREST: Mortality at 30 days. RESULTS: A total of 3886 healthy controls and 72 COVID-19 patients (10 non-survivors and 62 survivor patients at 30 days) were included. We found a trend to a higher rate of the alleles HLA-A*32 (p = 0.004) in healthy controls than in COVID-19 patients, and of the alleles HLA-B*39 (p = 0.02) and HLA-C*16 (p = 0.02) in COVID-19 patients than in healthy controls; however, all these p-values were not significant after correction for multiple comparisons. Logistic regression analysis showed that the presence of certain alleles was associated with higher mortality, such as the allele HLA-A*11 after controlling for SOFA (OR = 7.693; 95% CI = 1.063–55.650; p = 0.04) or APACHE-II (OR = 11.858; 95% CI = 1.524–92.273; p = 0.02), the allele HLA-C*01 after controlling for SOFA (OR = 11.182; 95% CI = 1.053–118.700; p = 0.04) or APACHE-II (OR = 17.604; 95% CI = 1.629–190.211; p = 0.02), and the allele HLA-DQB1*04 after controlling for SOFA (OR = 9.963; 95% CI = 1.235–80.358; p = 0.03). CONCLUSIONS: The new finding from our preliminary study of small sample size was that HLA genetic polymorphisms could be associated with COVID-19 mortality; however, studies with a larger sample size before definitive conclusions can be drawn. Elsevier España, S.L.U. y SEMICYUC. 2021-03 2020-09-06 /pmc/articles/PMC7474921/ http://dx.doi.org/10.1016/j.medin.2020.08.004 Text en © 2020 Elsevier España, S.L.U. y SEMICYUC. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
spellingShingle | Original Lorente, L. Martín, M.M. Franco, A. Barrios, Y. Cáceres, J.J. Solé-Violán, J. Perez, A. Marcos y Ramos, J.A. Ramos-Gómez, L. Ojeda, N. Jiménez, A. HLA genetic polymorphisms and prognosis of patients with COVID-19 |
title | HLA genetic polymorphisms and prognosis of patients with COVID-19 |
title_full | HLA genetic polymorphisms and prognosis of patients with COVID-19 |
title_fullStr | HLA genetic polymorphisms and prognosis of patients with COVID-19 |
title_full_unstemmed | HLA genetic polymorphisms and prognosis of patients with COVID-19 |
title_short | HLA genetic polymorphisms and prognosis of patients with COVID-19 |
title_sort | hla genetic polymorphisms and prognosis of patients with covid-19 |
topic | Original |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7474921/ http://dx.doi.org/10.1016/j.medin.2020.08.004 |
work_keys_str_mv | AT lorentel hlageneticpolymorphismsandprognosisofpatientswithcovid19 AT martinmm hlageneticpolymorphismsandprognosisofpatientswithcovid19 AT francoa hlageneticpolymorphismsandprognosisofpatientswithcovid19 AT barriosy hlageneticpolymorphismsandprognosisofpatientswithcovid19 AT caceresjj hlageneticpolymorphismsandprognosisofpatientswithcovid19 AT soleviolanj hlageneticpolymorphismsandprognosisofpatientswithcovid19 AT pereza hlageneticpolymorphismsandprognosisofpatientswithcovid19 AT marcosyramosja hlageneticpolymorphismsandprognosisofpatientswithcovid19 AT ramosgomezl hlageneticpolymorphismsandprognosisofpatientswithcovid19 AT ojedan hlageneticpolymorphismsandprognosisofpatientswithcovid19 AT jimeneza hlageneticpolymorphismsandprognosisofpatientswithcovid19 AT hlageneticpolymorphismsandprognosisofpatientswithcovid19 AT hlageneticpolymorphismsandprognosisofpatientswithcovid19 |